StockData
Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc. (RANI) stock

RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3043% above fair value
$0.65+0.09 (+15.86%)

Close on Nov 18, 2026Market cap $90.34MP/E –Yield –

Rani Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Rani Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$32.96M. For fiscal 2025 it was -$38.31M. The highest annual figure on record is -$16.54M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$38.31M–
FY2024Dec 31, 2024-$53.31M–
FY2023Dec 31, 2023-$66.10M–
FY2022Dec 31, 2022-$63.45M–
FY2021Dec 31, 2021-$51.60M–
FY2020Dec 31, 2020-$16.54M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$8.83M–
Q1 FY2026Mar 31, 2026-$8.34M–
Q4 FY2025Dec 31, 2025-$8.54M–
Q3 FY2025Sep 30, 2025-$7.26M–
Q2 FY2025Jun 30, 2025-$10.51M–
Q1 FY2025Mar 31, 2025-$12.01M–
Q4 FY2024Dec 31, 2024-$14.96M–
Q3 FY2024Sep 30, 2024-$11.80M–
Q2 FY2024Jun 30, 2024-$12.52M–
Q1 FY2024Mar 31, 2024-$14.03M–
Q4 FY2023Dec 31, 2023-$13.43M–
Q3 FY2023Sep 30, 2023-$17.86M–
Q2 FY2023Jun 30, 2023-$18.29M–
Q1 FY2023Mar 31, 2023-$16.52M–
Q4 FY2022Dec 31, 2022-$17.48M–
Q3 FY2022Sep 30, 2022-$16.34M–
Q2 FY2022Jun 30, 2022-$15.85M–
Q1 FY2022Mar 31, 2022-$13.78M–
Q4 FY2021Dec 31, 2021-$13.36M–
Q3 FY2021Sep 30, 2021-$27.78M–
Q2 FY2021Jun 30, 2021-$5.26M–
Q1 FY2021Mar 31, 2021-$5.20M–
Q4 FY2020Dec 31, 2020-$4.94M–
Q3 FY2020Sep 30, 2020-$2.83M–
Q2 FY2020Jun 30, 2020-$3.39M–

More Rani Therapeutics figures

See a number that looks wrong?